For a condition that affects an estimated 16 million Americans and ranks as the fourth leading cause of death, chronic obstructive pulmonary disease receives surprisingly little diagnostic rigor in primary care. The gold standard test—spirometry—is performed in only about four of every ten visits where COPD is suspected, a figure that has barely budged in the past two decades. This stall persists despite clear guidelines, widespread awareness campaigns, and mounting evidence that clinical diagnosis alone misses a substantial fraction of cases. Understanding why requires a close look at the incentives, workflows, and beliefs that keep spirometry on the shelf.

The Forty Percent Stall: A Diagnostic Gap That Won't Close

National surveys and claims analyses consistently place spirometry use for new COPD diagnoses in US primary care at roughly 35 to 45 percent. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has recommended spirometry as the essential test for diagnosis since its first report in 2001. The US Preventive Services Task Force, the American Thoracic Society, and the American College of Chest Physicians all echo this position. Yet in practice, most patients who present with cough, dyspnea, or sputum production receive a diagnosis based on history and physical exam alone.

This diagnostic gap matters because COPD is both underdiagnosed and misdiagnosed. Studies using post-bronchodilator spirometry in primary care populations have found that up to half of patients with airflow obstruction were previously undiagnosed. Conversely, many patients labeled with COPD have normal spirometry, leading to unnecessary treatment and stigma. The stall persists despite quality improvement initiatives, public health campaigns, and even financial penalties for hospitals with high COPD readmission rates—a policy that, as we've covered in a related piece, has had unintended consequences on medication use.

The forty percent figure is not uniformly distributed. Rates are lower in rural clinics, smaller practices, and settings with fewer resources. They are higher in integrated delivery systems and academic medical centers. But the national average has remained stubbornly flat, suggesting that the barriers are structural rather than merely a matter of awareness. The gap represents a failure not of knowledge but of implementation.

Why Spirometry Stays on the Shelf

Primary care visits in the United States average about fifteen to twenty minutes. Adding spirometry—which requires patient coaching, multiple forced exhalations, and interpretation of flow-volume curves—can add ten minutes or more. For a clinician juggling diabetes, hypertension, and preventive screenings, the perceived time cost is prohibitive. Many physicians report that they rely on clinical impression because it feels faster, even if it is less accurate.

Equipment and maintenance present another hurdle. Office spirometers cost anywhere from a few hundred to several thousand dollars, and they require regular calibration, cleaning, and quality control. Small practices often lack the staff or expertise to maintain them. Disposable mouthpieces and filters add per-test costs that may not be fully reimbursed. A 2022 survey of primary care physicians found that one-third cited equipment cost as a major barrier, and nearly half said they lacked trained personnel to perform the test reliably.

Reimbursement rates compound the problem. Medicare pays roughly $20 to $40 for spirometry, depending on the specific code and geographic adjustment. That amount barely covers the supplies and technician time, let alone the physician's interpretation. Private insurers vary widely, and some require prior authorization or impose restrictive medical necessity criteria. For a practice operating on thin margins, spirometry can feel like a money-losing proposition.

Perhaps the most insidious barrier is the belief that history and exam are sufficient. Many clinicians, particularly those trained before spirometry became the standard, trust their ability to detect obstruction through auscultation and symptom patterns. Yet studies consistently show that physical exam findings—wheezing, prolonged expiration, reduced breath sounds—have poor sensitivity for mild-to-moderate COPD. The confidence is misplaced, but it persists because it is reinforced by experience: most patients who present with typical symptoms do have some lung abnormality, and treatment often helps regardless of the exact diagnosis.

What the Evidence Says About Missed COPD

The consequences of underdiagnosis are not abstract. A systematic review published in 2023 estimated that 60 to 80 percent of COPD cases in the United States remain undiagnosed, with higher rates among women, non-smokers, and minority populations. These individuals progress without the benefit of bronchodilators, pulmonary rehabilitation, or vaccination against respiratory infections. Their lung function declines faster, and they are more likely to present with an exacerbation requiring hospitalization as their first encounter with the healthcare system.

Misdiagnosis is equally problematic. Asthma and COPD share overlapping symptoms and can coexist, but their management differs. Without spirometry, patients with asthma may receive long-acting bronchodilators without anti-inflammatory therapy, while those with COPD may be overtreated with inhaled corticosteroids. A claims analysis from 2021 found that nearly one in three patients diagnosed with COPD in primary care had no evidence of obstruction on subsequent spirometry, and many of those were later reclassified as asthma or simply as symptomatic smokers.

Delayed diagnosis also affects prognosis. The annual loss of lung function in COPD is accelerated by exacerbations, and early intervention with smoking cessation and pharmacotherapy can slow that decline. A missed diagnosis of five years may translate into a permanent loss of 200 to 300 milliliters of forced expiratory volume—enough to shift a patient from mild to moderate disease. The evidence is clear that earlier detection improves outcomes, yet the system continues to prioritize reactive treatment over proactive diagnosis.

Where the Model Works: Lessons From Integrated Systems

Not every healthcare setting struggles with spirometry. Kaiser Permanente, the large integrated delivery system, has reported spirometry rates above 60 percent for new COPD diagnoses. Their model includes on-site equipment in every primary care clinic, dedicated respiratory therapists who perform and interpret tests, and electronic health record prompts that flag patients with smoking history and respiratory symptoms. The system also ties quality metrics to physician compensation, creating a financial incentive to complete the test.

The United Kingdom's National Health Service provides another example. Under the Quality and Outcomes Framework (QOF), general practices receive financial rewards for maintaining a registry of COPD patients with spirometry-confirmed diagnosis. By 2019, over 70 percent of COPD diagnoses in UK primary care were supported by spirometry, up from roughly 50 percent a decade earlier. Nurse-led spirometry clinics, where trained practice nurses perform the test and interpret results under protocol, reduced the burden on physicians and improved access.

These examples show that the barriers are surmountable with the right combination of resources, incentives, and workflow redesign. But they also highlight the gap between integrated systems and the fragmented, fee-for-service environment that characterizes much of US primary care. Replicating Kaiser's model in a three-physician practice in rural Montana would require substantial investment and organizational support that is not currently available.

The Reimbursement and Policy Roadblocks

Medicare's payment for spirometry has not kept pace with inflation. The current fee for CPT code 94010 (spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement) is approximately $25 to $40, depending on the region. That amount must cover equipment amortization, supplies, staff time, and physician interpretation. Many practices report that the test takes 15 to 20 minutes of staff time alone, making the effective reimbursement well below that of a brief office visit.

Private insurance reimbursement varies widely. Some plans bundle spirometry into a global payment for preventive care, while others require prior authorization and documentation of specific symptoms. A 2024 analysis by the American Lung Association found that prior authorization was required for spirometry in 12 states for at least one major insurer, adding administrative burden that discourages use. The process can take days or weeks, by which time the patient may have left the practice or started empiric treatment.

Policy interventions at the state level have been limited. Only a handful of states mandate spirometry for COPD diagnosis in their Medicaid programs, and none have enacted laws requiring primary care practices to offer the test. The Centers for Medicare & Medicaid Services has not adopted a quality measure for spirometry use in COPD, unlike the measures for cancer screening or diabetes control. Without a clear regulatory push, the default remains clinical diagnosis.

New Devices and Workflow Hacks That Could Help

Technology may offer a partial solution. Handheld spirometers, some costing under $500, are now available with smartphone apps that guide patients through the maneuver and automatically interpret results. These devices can be used in the exam room or sent home for pre- and post-bronchodilator testing. Early studies suggest that the accuracy of these devices is comparable to traditional office spirometers, though quality control remains a concern.

Workflow changes can also reduce the time burden. Pre-visit questionnaires that screen for respiratory symptoms and smoking history can identify high-risk patients before they see the physician. A dedicated spirometry visit, scheduled separately from the acute care visit, allows staff to perform the test without time pressure. Some practices have implemented a "spirometry hour" once a week, where patients with suspected COPD are clustered for batch testing.

Tele-supervision is another emerging option. A respiratory therapist can guide a patient through spirometry via video call, allowing the test to be performed at home or in a community clinic without on-site expertise. This model has been used successfully in rural Australia and is being piloted in several US health systems. The interpretation can be done asynchronously, with results entered into the electronic health record for the physician to review.

Short protocols are also gaining traction. The standard pre- and post-bronchodilator spirometry takes about 20 minutes, but a simplified protocol using only the pre-bronchodilator measurement can be performed in under 10 minutes. While less definitive, it can serve as a screening tool to identify patients who need full testing. The trade-off is a higher rate of false positives, but in a setting where the alternative is no testing at all, the net benefit may still be positive.

Counterarguments: When Spirometry Might Not Be the Answer

Not all voices in primary care argue for universal spirometry. Some clinicians contend that in patients with clear-cut symptoms and a heavy smoking history, the diagnosis is virtually certain, and spirometry adds little to management. They point to studies showing that treatment decisions—smoking cessation counseling, bronchodilator prescriptions, vaccination—do not always change after spirometry results are known. For example, a 2019 trial in primary care found that patients with clinically diagnosed COPD who received spirometry had similar rates of medication adjustments and exacerbation outcomes as those who did not, over a one-year follow-up.

Others raise concerns about overdiagnosis. Screening asymptomatic smokers with spirometry can identify mild airflow obstruction that may never progress to symptomatic disease. Labeling such individuals with COPD can cause psychological distress, insurance discrimination, and unnecessary medication use. The US Preventive Services Task Force specifically recommends against population screening for COPD in asymptomatic adults, citing insufficient evidence of net benefit. This nuance is often lost in advocacy for higher spirometry rates.

There is also a practical argument: in many resource-limited settings, the opportunity cost of spirometry is real. The 20 minutes spent on a test could be used for counseling on smoking cessation, which remains the most impactful intervention for COPD. If spirometry replaces counseling rather than complements it, the net benefit may be negative. These counterarguments do not undermine the value of spirometry in uncertain cases, but they suggest that the goal should not be 100 percent testing, but rather targeted testing in patients where the diagnosis is unclear or where results will change management.

What a Clinician Can Do Next Week

For primary care clinicians frustrated by the stall, several steps can be taken without waiting for policy change. The first is to identify undiagnosed patients using a simple screener: anyone over 40 with a smoking history of 20 pack-years or more and at least one respiratory symptom (cough, sputum, dyspnea) should be offered spirometry. This approach, recommended by the US Preventive Services Task Force for case-finding, can be implemented with a paper form or an EHR prompt.

The second step is to schedule a dedicated spirometry visit. Rather than trying to fit the test into a busy acute care slot, practices can book a separate 20-minute appointment with a medical assistant or nurse trained in spirometry. Many professional organizations offer free online training modules that take less than an hour to complete. The cost of a handheld spirometer can be recouped after a few dozen tests if reimbursement is consistent.

For practices without on-site equipment, partnering with a local pulmonary function laboratory or hospital outpatient department can provide access. A referral for spirometry is a simple order that can be filled within a week in most communities. The key is to make it a routine part of the diagnostic workup, not an afterthought reserved for complicated cases.

Finally, tracking practice-level rates can help identify the gap. Many electronic health records can generate a report of how many patients with a new COPD diagnosis have spirometry on file. Seeing the number—whether 30 percent or 60 percent—can motivate change more effectively than any guideline. The goal is not perfection but progress, and small improvements can have outsized effects on patient outcomes over time.

This article is for informational purposes only and does not constitute medical advice. Clinicians should consult current guidelines and individual patient circumstances when making diagnostic decisions.